| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/16/2003 | US20030013674 Gene therapy; in situ supplying of genes; nucleic acid complex |
| 01/16/2003 | US20030013669 Method of treating HIV infection and related secondary infections thereof |
| 01/16/2003 | US20030013666 Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| 01/16/2003 | US20030013644 Complexing; therapy for genetic defects |
| 01/16/2003 | US20030013641 Complexing drug with diketopiperazine; washing; separation of impurities |
| 01/16/2003 | US20030013634 Synthesis of small particles |
| 01/16/2003 | US20030013179 Enzymatic polypeptide for use in the treatment of lysosomal storage disorders |
| 01/16/2003 | US20030013164 Generating linoleic acid derivatives; obtain chemical intermediates, incubate with lipase, recover fatty acid conjugated to linoleic acid |
| 01/16/2003 | US20030013095 Nuclcic acid enzyme for use in the prevention and treatment of infections and cancer |
| 01/16/2003 | US20030012953 Non-stoichiometric non- equilibrium material, and the material is a nanostructured material;e.g., boron nitrides, tin oxides, titanium carbides and nickel ferrites |
| 01/16/2003 | US20030012952 Nanotechnology for electrochemical and energy devices |
| 01/16/2003 | US20030012926 Substrates for powder deposition containing conductive domains |
| 01/16/2003 | US20030012892 Precipitation of solid particles from droplets formed using focused acoustic energy |
| 01/16/2003 | US20030012826 Carotenoids; vitamins E, D, & C; thiamine; riboflavin; niacin; folic acid; pyridoxine; biotin; pantothenic acid; cobalamin; magnesium; manganese; zinc; selenium; chromium; copper; alpha lipoic acid; and lutein; added iron free |
| 01/16/2003 | US20030012820 Less than 30 % of the particles exhibit a particle size of greater than 425 micrometers and greater than 80 % of the particles exhibit a particle size of greater than 45 micrometers; improved robustness and flexibility |
| 01/16/2003 | US20030012819 Method of preparing biological materials and preparations produced using same |
| 01/16/2003 | US20030012818 Bioactive molecule that is a non-glycosylated member of the cystine knot growth factor superfamily is physically entrapped in the polymeric matrix. |
| 01/16/2003 | US20030012817 Modified amino acids and derivatives can form non-covalent mixtures with active biological agents and in an alternate embodiment can releasably carry active agents. Modified amino acids can also form drug containing microspheres. |
| 01/16/2003 | US20030012815 Sustained-release preparation and process for producing the same |
| 01/16/2003 | US20030012814 At least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. |
| 01/16/2003 | US20030012813 Cationic lipid with a lipophilic group derived from cholesterol; an amide or carbamate linker bond; an alkylene spacer arm; and a cationic primary, secondary, tertiary or quaternary amino group. facilitating nucleic acid transfer |
| 01/16/2003 | US20030012812 Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| 01/16/2003 | US20030012811 Lint incorporated into an adhesive plaster or patch, for application to the skin, for delivering an aroma; exposed surface of the plaster when worn includes a central hole so that the aroma from the lint may escape therethrough. |
| 01/16/2003 | US20030012808 Member for application of ointment and ointment patch employing the same |
| 01/16/2003 | US20030012806 Drug releasing elastic band and method |
| 01/16/2003 | US20030012798 Physiologically active substance eem-s originating in mushroms, process for producing the same and drugs |
| 01/16/2003 | US20030012797 Substantially free of or having a minimum content of a fat and oil material and an emulsifier in an encapsulated liquid or medicinal liquid; contains a dietary fiber in an amount of 5 to 90% by weight |
| 01/16/2003 | US20030012784 Methods for treatment of inflammatory diseases |
| 01/16/2003 | US20030012778 Reversibly inactivated acidified plasmin |
| 01/16/2003 | US20030012770 Recombinant p53 adenovirus methods and compositions |
| 01/16/2003 | US20030012765 First polysaccharide crosslinked to second polysaccharide, selected from hyaluronic acid, dextran, dextran sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparin, heparan sulfate and alginate |
| 01/16/2003 | US20030012758 Hair composition containing at least one of (i) anionic, amphoteric, and nonionic fixing polymers; (ii) beneficial agents; and (iii) hair dyes; capable of directly depositing on the hair said at least one component. |
| 01/16/2003 | US20030012742 Porous particles comprising excipients for deep lung delivery |
| 01/16/2003 | US20030012741 Process for the preparation of micronised collagen, and its therapeutic applications |
| 01/16/2003 | US20030012740 Aerosols especially containing benzotropine, pergolide, ropinerole, amantadine or deprenyl. |
| 01/16/2003 | US20030012739 Containing rosiglitazone maleate and a fluid carrier. |
| 01/16/2003 | US20030012738 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
| 01/16/2003 | US20030012737 Delivery of diphenhydramine through an inhalation route |
| 01/16/2003 | US20030012734 Biodegradable hydrogel having a visualization agent that reflects or emits light at a wavelength detectable to a human eyeast partially disposed within the interior. |
| 01/16/2003 | US20030012325 Mixture containing rare earth and the use thereof |
| 01/16/2003 | US20030011088 Apparatus for preparing microparticles using liquid-liquid extraction |
| 01/16/2003 | US20030010808 Methods for hermetically sealing microchip reservoir devices |
| 01/16/2003 | CA2452874A1 Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 01/16/2003 | CA2452872A1 Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 01/16/2003 | CA2452835A1 Aromatic sulfenates for type i phototherapy |
| 01/16/2003 | CA2452298A1 Lanolin substitute, production method thereof and applications of same |
| 01/16/2003 | CA2452257A1 Pharmaceutical formulations and ligands for use therein; mimetics for uea-1 |
| 01/16/2003 | CA2452241A1 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | CA2451742A1 Treatment of parasitic disease |
| 01/16/2003 | CA2451741A1 Peyers's patch and/or m-celle targeting ligands |
| 01/16/2003 | CA2451360A1 Method and composition for prolonging the residence time of drugs in the gut |
| 01/16/2003 | CA2449828A1 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 01/16/2003 | CA2447886A1 Compositions for removing human cerumen |
| 01/16/2003 | CA2433583A1 Composition of insulin for nasal administration |
| 01/15/2003 | EP1275397A2 Medicament for local use |
| 01/15/2003 | EP1275396A2 Use of angiotensin II fragments and analogs thereof in tissue repair |
| 01/15/2003 | EP1275395A2 Use of hyaluronic acid for preparing a composition for vaginal use |
| 01/15/2003 | EP1275391A1 Pharmaceutical compositions containing irbesartan and a diuretic |
| 01/15/2003 | EP1275387A1 Fenofibrate pharmaceutical composition with a higher bioavailability and its manufacturing process |
| 01/15/2003 | EP1275386A1 Solid dispersion with improved absorbability |
| 01/15/2003 | EP1275383A1 Modified release pharmaceutical composition containing Bupropion HCI as active substance |
| 01/15/2003 | EP1275382A2 Hyperforin as cytostatic agent and hyperforin ointment or cream as application form |
| 01/15/2003 | EP1275381A1 Time-release coated solid compositions for oral administration |
| 01/15/2003 | EP1275380A1 Use of microparticles with adsorbed antigen to stimulate immune responses |
| 01/15/2003 | EP1275379A2 Basic granulate comprising (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one |
| 01/15/2003 | EP1275378A2 Particulate construct comprising polyhydroxyalkanoate and method for producing it |
| 01/15/2003 | EP1275377A1 Granulates containing liposoluble substances and process of preparation thereof |
| 01/15/2003 | EP1275376A2 Two-phase hydrogel for application in drops at the eye |
| 01/15/2003 | EP1275375A1 Aerosol compositions |
| 01/15/2003 | EP1275374A1 Buccal, non-polar spray or capsule comprising analgesics or alkaloids |
| 01/15/2003 | EP1275373A1 Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof |
| 01/15/2003 | EP1274750A1 Hydrophilic polymers, pressure sensitive adhesives and coatings |
| 01/15/2003 | EP1274473A2 Antimicrobial bioabsorbable materials |
| 01/15/2003 | EP1274459A2 Sustained release formulations comprising growth hormone |
| 01/15/2003 | EP1274449A2 Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
| 01/15/2003 | EP1274447A1 Pharmaceutical composition with a content of calcium or mixture of calcium and vitamin d or mixture of calcium and magnesium in a new formulation |
| 01/15/2003 | EP1274446A1 Polysaccharidic esters of n-derivatives of glutamic acid |
| 01/15/2003 | EP1274443A1 Micelles |
| 01/15/2003 | EP1274441A1 Respiratory compositions |
| 01/15/2003 | EP1274440A1 Medical combinations comprising tiotropium and mometasone |
| 01/15/2003 | EP1274439A1 Medical combination comprising salmeterol and budesonide |
| 01/15/2003 | EP1274438A1 Medical combinations comprising tiotropium and budesonide |
| 01/15/2003 | EP1274437A1 Medical combinations comprising tiotropium and fluticasone proprionate |
| 01/15/2003 | EP1274436A1 Medical compositions comprising (r,r)-formoterol und rofleponide |
| 01/15/2003 | EP1274435A1 Medical combinations comprising formoterol and budesonide |
| 01/15/2003 | EP1274434A1 Medical combinations comprising tiotropium and rofleponide |
| 01/15/2003 | EP1274433A1 Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
| 01/15/2003 | EP1274432A1 Compositions containing itraconazole with improved bioavailability and narrow intra- and inter-individual variation of its absorption |
| 01/15/2003 | EP1274429A1 Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia |
| 01/15/2003 | EP1274427A1 Formulation of substituted benzimidazoles |
| 01/15/2003 | EP1274425A1 Rapid-onset formulation of a selective cyclooxigenase-2 inhibitor |
| 01/15/2003 | EP1274414A1 Nasal administration of agents for the treatment of gastroparesis |
| 01/15/2003 | EP1274412A1 Pharmaceutical formulation |
| 01/15/2003 | EP1274406A2 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
| 01/15/2003 | EP1274405A2 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication |
| 01/15/2003 | EP1274404A1 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents |
| 01/15/2003 | EP1274403A2 Particulate composition |
| 01/15/2003 | EP1274402A1 Pharmaceutical composition for the controlled release of paracetamol |
| 01/15/2003 | EP1274401A1 Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
| 01/15/2003 | EP1274400A1 Physically stabilized dry powder formulations |